Clinical trials: Atrial Fibrillation (Permanent)
Systolic Heart Failure, Atrial Fibrillation (Permanent)
Junctional AV Ablation in CRT-D: JAVA-CRT
Cardiac resynchronization therapy (CRT) is a demonstrably effective device intervention for patients with heart failure with reduced ejection fraction and specific indication.
- Trial name
- NCT02946853
- Testing
- Atrioventricular junctional (AVJ) ablation, Cardiac resynchronization therapy - defibrillator
- Where
- 21 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Rochester
Permanent Atrial Fibrillation
Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Atrial fibrillation is a common heart rhythm disturbance, causing important discomfort for patients, a high risk of stroke, frequent hospital admissions and a two-fold increase in death.
- Trial name
- RATE-AF (NCT02391337)
- Testing
- Bisoprolol, Digoxin
- Where
- 2 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- University of Birmingham
Persistent or Permanent Non-valvular Atrial Fibrillation
Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.
- Trial name
- NCT00623779
- Testing
- AZD0837, Aspirin
- Where
- 38 sites in Denmark, Norway and 4 more
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Persistent or Permanent Nonvalvular Atrial Fibrillation
Long-term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and…
- Trial name
- NCT00645853
- Testing
- AZD0837, VKA INR 2-3
- Volunteers
- 523 people
- Sponsor
- AstraZeneca
Permanent Atrial Fibrillation
Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
The purpose of this study is to monitor heart rate regularization in patients with permanent atrial fibrillation and standard indication for single chamber rate adaptive pacing VVI(R).
- Trial name
- RARE-PEARL (NCT00246805)
- Testing
- Vitatron pacemaker C20 SSIR or T20 SSIR models
- Where
- 13 sites in Italy
- Volunteers
- 67 people
- Sponsor
- Medtronic BRC